• Owen D Lyons, John S Floras, Alexander G Logan, Robert Beanlands, Joaquin Durán Cantolla, Michael Fitzpatrick, John Fleetham, John Kimoff R R McGill University Health Centre, Montreal, QC, Canada., Richard S T Leung, Geraldo Lorenzi Filho, Pierre Mayer, Lisa Mielniczuk, Debra L Morrison, Clodagh M Ryan, Frederic Series, George A Tomlinson, Anna Woo, Michael Arzt, Sairam Parthasarathy, Stefania Redolfi, Takatoshi Kasai, Gianfranco Parati, Diego H Delgado, T Douglas Bradley, and ADVENT-HF Investigators.
• Women's College Hospital, Toronto, ON, Canada.
• Eur. J. Heart Fail. 2017 Apr 1; 19 (4): 579-587.

IntroductionBoth types of sleep-disordered breathing (SDB), obstructive and central sleep apnoea (OSA and CSA, respectively), are common in patients with heart failure and reduced ejection fraction (HFrEF). In such patients, SDB is associated with increased cardiovascular morbidity and mortality but it remains uncertain whether treating SDB by adaptive servo-ventilation (ASV) in such patients reduces morbidity and mortality.AimADVENT-HF is designed to assess the effects of treating SDB with ASV on morbidity and mortality in patients with HFrEF.MethodsADVENT-HF is a multicentre, multinational, randomized, parallel-group, open-label trial with blinded assessment of endpoints of standard medical therapy for HFrEF alone vs. with the addition of ASV in patients with HFrEF and SDB. Patients with a history of HFrEF undergo echocardiography and polysomnography. Those with a left ventricular ejection fraction ≤45% and SDB (apnoea-hypopnoea index ≥15) are eligible. SDB is stratified into OSA with ≥50% of events obstructive or CSA with >50% of events central. Those with OSA must not have excessive daytime sleepiness (Epworth score of ≤10). Patients are then randomized to receive or not receive ASV. The primary outcome is the composite of all-cause mortality, cardiovascular hospital admissions, new-onset atrial fibrillation requiring anti-coagulation but not hospitalization, and delivery of an appropriate discharge from an implantable cardioverter-defibrillator not resulting in hospitalization during a maximum follow-up time of 5 years.ConclusionThe ADVENT-HF trial will help to determine whether treating SDB by ASV in patients with HFrEF improves morbidity and mortality.© 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology.

29 keywords...

hide…